Kinetics Medical No Load (MEDRX)
30.32
-0.15 (-0.49%)
USD |
Aug 18 2022
Returns Chart
Key Stats
Customize
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 1.39% | 18.04M | 0.86% | 1.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -472973.3 | -7.62% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks long-term growth of capital. The fund is a non-diversified fund that invests all of its investable assets in the Medical Portfolio, a series of Kinetics Portfolios Trust. The Portfolio invests at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants, and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries, with an emphasis toward companies engaged in cancer research and drug development. It is non-diversified. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | MEDRX |
| Equity Style | Large Cap/Value |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Kinetics |
| Prospectus Benchmark Index | |
| S&P 500 TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Bruce Abel | 22.85 yrs |
| Peter Doyle | 22.85 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
33
-472973.3
-3.337B
Category Low
7.804B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of July 31, 2022
Performance Versus Category
As of August 18, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of August 18, 2022.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Bristol-Myers Squibb Co | 9.44% | 75.30 | 1.55% |
| AbbVie Inc | 8.92% | 141.86 | 0.40% |
| Eli Lilly and Co | 8.67% | 322.77 | 1.91% |
| Pfizer Inc | 8.55% | 49.16 | 1.18% |
| Johnson & Johnson | 6.83% | 169.56 | 1.67% |
| Novartis AG ADR | 6.76% | 85.74 | 0.97% |
| Merck & Co Inc | 6.32% | 92.07 | 0.73% |
| Amgen Inc | 5.32% | 250.91 | 0.48% |
| AstraZeneca PLC ADR | 5.11% | 67.18 | 1.02% |
| Biogen Inc | 4.35% | 214.29 | -0.95% |
Basic Info
| Investment Strategy | |
| The investment seeks long-term growth of capital. The fund is a non-diversified fund that invests all of its investable assets in the Medical Portfolio, a series of Kinetics Portfolios Trust. The Portfolio invests at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants, and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries, with an emphasis toward companies engaged in cancer research and drug development. It is non-diversified. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | MEDRX |
| Equity Style | Large Cap/Value |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Kinetics |
| Prospectus Benchmark Index | |
| S&P 500 TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Bruce Abel | 22.85 yrs |
| Peter Doyle | 22.85 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (8-18-22) | 0.86% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield (12-30-10) | Upgrade |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 18.28 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of March 31, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 9/30/1999 |
| Last Annual Report Date | 12/31/2021 |
| Last Prospectus Date | 4/30/2022 |
| Share Classes | |
| KRXAX | A |
| KRXCX | C |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |